Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study

Autor:	Shun-Sheng Wu, Fu-Yuan Siao, Hsu-Heng Yen, Pei-Yuan Su, Jun-Hung Lai, Yu-Chun Hsu, Siou-Ping Huang, I-Ling Liu, Yang-Yuan Chen, Hung-Ming Chen, Chih-Ta Yao, Ya-Huei Zeng
Rok vydání:	2021
Předmět:	therapy medicine.medical_specialty Cirrhosis business.industry Anemia cirrhosis Hepatitis C virus General Medicine Hepatitis C Glecaprevir Jaundice medicine.disease medicine.disease_cause Article Pibrentasvir Regimen Internal medicine medicine Medicine hepatitis C medicine.symptom business compensated cirrhosis
Zdroj:	Journal of Clinical Medicine Journal of Clinical Medicine, Vol 10, Iss 5236, p 5236 (2021) Volume 10 Issue 22
ISSN:	2077-0383
Popis:	Background: Glecaprevir/pibrentasvir is a protease inhibitor-containing pangenotypic direct-acting antiviral regimen that has been approved for the treatment of chronic hepatitis C. The present study aimed to evaluate the safety and efficacy of glecaprevir/pibrentasvir in patients with compensated cirrhosis in a real-world setting. Methods: We evaluated the real-world safety and efficacy of glecaprevir/pibrentasvir in patients with compensated cirrhosis from five hospitals in the Changhua Christian Care System, who underwent treatment between August 2018 and October 2020. The primary endpoint was a sustained virological response observed 12 weeks after completion of the treatment. Results: Ninety patients, including 70 patients who received the 12-week therapy and 20 patients who received the 8-week therapy, were enrolled. The mean age of the patients was 65 years, and 57.8% of the patients were males. Sixteen (17.8%) patients had end-stage renal disease, and 15 (16.7%) had co-existing hepatoma. The hepatitis C virus genotypes 1 (40%) and 2 (35.6%) were most common. The common side effects included anorexia (12.2%), pruritus (7.8%), abdominal discomfort (7.8%), and malaise (7.8%). Laboratory adverse grade ≥3 events included anemia (6.3%), thrombocytopenia (5.1%), and jaundice (2.2%). The overall sustained virological response rates were 94.4% and 97.7% in the intention-to-treat and per-protocol analyses, respectively. Conclusions: the glecaprevir/pibrentasvir treatment regimen was highly effective and well tolerated among patients with compensated cirrhosis in the real-world setting.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bada9497f53273e08c50097b64e72b7 https://doi.org/10.3390/jcm10225236 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.